Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a nanotransferosome formulation of finasteride (FI-GO-NTF) in an Aloe vera gel significantly improved scalp permeation and antibacterial activity compared to standard formulations, suggesting safe and effective potential for alopecia areata treatment.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This review discusses potential advancements in topical dutasteride formulations for treating androgenic alopecia and reports no clinical results, highlighting a focus on improving skin penetration and availability.

The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.

This study found that in an androgenetic alopecia mouse model, phospholipid-bile salt mixed micelles for topical Finasteride delivery improved hair regrowth and reduced systemic absorption compared to a hydroalcoholic solution, suggesting a safer and more effective treatment option.

This study found that finasteride niosomes may enhance hair follicle drug accumulation and promote hair regeneration in androgenetic alopecia mice more effectively than current finasteride formulations.

This review discusses the potential use of liposomal formulations to enhance the effectiveness of cosmeceutical delivery through the skin barrier, with no new clinical results reported.

This review highlights the potential of nanotechnology-based formulations in hair care and treatment, emphasizing how these innovative materials can enhance the stability, efficacy, and safety of active compounds while addressing the limitations of conventional formulations.

This review examines recent advances in androgenetic alopecia treatment, highlighting how multifunctional plant extracts combined with nanotechnology could improve topical therapy efficacy by enhancing local drug bioavailability and targeting, addressing limitations of existing treatments.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

In this study, a film-forming spray with rosemary essential oil increased hair density in volunteers over 16 weeks, suggesting it has potential efficacy for treating androgenetic alopecia by enhancing hair density restoration.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

Niosomes are a promising and effective way to deliver drugs through the skin.

This review summarizes recent advances in alopecia management, focusing on combining synthetic and herbal therapies with innovative drug delivery systems like nanocarriers to enhance effectiveness and reduce side effects, while noting challenges with skin penetration and bioavailability.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study found that a lipid nanoemulsion-based gel of finasteride for topical use improved hair growth and was effective against alopecia, with slow skin permeation and increased efficacy compared to a testosterone-treated group.

In this review, researchers explored the potential of topical finasteride as an innovative treatment for male pattern hair loss, addressing the limitations of oral finasteride, such as side effects and inconsistent effectiveness.

Finasteride solution helps treat hair loss.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.